Frontier Biotechnologies Inc. news

On July 15, 2021, The openning ceremony of a new state of the art peptide manufacture facility was held in Jintang, Chengdu. The successful completion of the facility marks the successful industrialization of Aikening® in Jintang.

Aiming at intelligent manufacturing, high efficiency and eco system, and a quality system to be certified by the US FDA, EU EMA and China NMPA, the peptide production facility includes a R&D center, a pilot plant, production lines, and business cente

Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual therapy to treat people living with HIV who have failed initial treatment.

The approval of Aikening® is based on the pivotal phase 3 TALENT (Test Albuvirtide in Experienced Patients), which

Shanghai Ruijin Hospital recently announced that it has initiated an investigator-initiated clinical trial (IIT) to evaluate the safety and efficacy of Bofutrelvir administered by inhalation for post-exposure prophylaxis in close contacts of COVID-19 (NCT05415241). It is a single-arm, open-label, multi-dose exploratory clinical study with an enrolment of ~60 subjects who are close contacts of COVID-19 patients. Data from preclinical studies has shown that Bofutrelvir administered by inhalatio

Frontier Biotech (stock code: 688221.SH) announced that the Phase II/III clinical study protocol of FB2001 (generic name: Bofutrelvir) is approved by the Center for Drug Evaluation, NMPA. The study is a worldwide multi-center, randomized, double-blind and placebo-controlled Phase II/III trial to evaluate the safety and efficacy of Bufutrelvir for hospitalized Covid-19 patients. Frontier Biotech has signed on with a leading global clinical CRO to conduct this pivotal trial and the study is soo

Frontier Biotech (stock code: 688221.SH) announces that it signs an agreement with R-Pharm, JSC, one of the largest pharmaceutical companies in Russia, for registration and commercialization of Aikening® (generic name: Albuvirtide) in Russia.

Cheryl Tan, Global Head of Frontier Biotech`s International Businesses, said, “Aikening® is the first new long-acting antiretroviral drug independently developed by Frontier Biotech. Since its launch in Chi